BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35347593)

  • 1. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
    Vater LB; Lefebvre B; Turk A; Clasen SC
    Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoropyrimidine-Associated Cardiotoxicity.
    Kanduri J; More LA; Godishala A; Asnani A
    Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
    Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
    Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
    Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
    ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
    Peng T; Ouyang Y; Tong K
    Medicine (Baltimore); 2019 Jan; 98(2):e14057. PubMed ID: 30633206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
    Saif MW
    Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
    Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
    Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
    Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm.
    Clasen SC; Ky B; O'Quinn R; Giantonio B; Teitelbaum U; Carver JR
    J Gastrointest Oncol; 2017 Dec; 8(6):970-979. PubMed ID: 29299356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-fluorouracil and cardiotoxicity: a review.
    Sara JD; Kaur J; Khodadadi R; Rehman M; Lobo R; Chakrabarti S; Herrmann J; Lerman A; Grothey A
    Ther Adv Med Oncol; 2018; 10():1758835918780140. PubMed ID: 29977352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
    Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
    Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
    Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
    Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Fluorouracil Rechallenge After Cardiotoxicity.
    Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
    Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
    Jensen SA; Sørensen JB
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
    More LA; Lane S; Asnani A
    Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
    Wu Z; Deng Y
    Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
    Li C; Ngorsuraches S; Chou C; Chen L; Qian J
    Crit Rev Oncol Hematol; 2021 Jun; 162():103346. PubMed ID: 33930532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.